Imatinib mesylate is a tyrosine kinase inhibitor used primarily in the treatment of leukemia. Chronic Myeloid Leukemia (CML) cells contain a hybrid tyrosine kinase BCR/ABL that works to provide the cancer cell with ATP at an uncontrolled rate. Imatinib mesylate inhbiits this hybrid protein to slow cell growth and promote apoptosis.
CAS Number
220127-57-1
Molecular Formula
C29H31N7O•CH3SO3H
Molecular Weight
589.71
Mechanism of Action
Imatinib mesylate binds to the ATP binding site of the BCR/ABL tyrosine kinase and stabilizes its inactive form.
Storage Conditions
2-8°C